Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Exagen Inc.NASDAQ: XGN
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $7.1M rose 11.4% year over year, behind the +23.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 4.4% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Cost of revenue amounted to 41.7% of revenue in FY2025, up 1.2 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.4% toward the trailing-twelve-month pace of +23.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 27.78M USD
- Year-over-year change
- +23.3%
- 4-year CAGR
- +7.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.78M | +23.3% |
| FY2024 | 2024-12-31 | 22.53M | -2.4% |
| FY2023 | 2023-12-31 | 23.09M | -4.6% |
| FY2022 | 2022-12-31 | 24.21M | +17.6% |
| FY2021 | 2021-12-31 | 20.59M | — |
Cost of Revenue vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 cost of revenue of $28.5M is the 4th highest of the 11 companies compared; the peer median is $15.41M.
- Its year-over-year change of +23.5% is the 3rd highest of 9, against a peer median of +10.1%.
- Cost of revenue amounts to 41.7% of revenue for XGN, versus a peer median of 32.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $437.4M | +13.2% | +11.4% | 57.1% | |
| LTM Mar 2026 | $93.03M | — | +7.0% | 68.8% | |
| FY2025 | $43.43M | +24.4% | +34.5% | 40.3% | |
| LTM Mar 2026 | $28.5M | +23.5% | +4.7% | 41.7% | |
| LTM Mar 2026 | $27.87M | -7.8% | +4.2% | 66.7% | |
| LTM Mar 2026 | $16.42M | +24.9% | -18.7% | 7.5% | |
| LTM Mar 2026 | $14.39M | +12.3% | +16.5% | 46.1% | |
| LTM Mar 2026 | $11M | -1.8% | -4.7% | 13.8% | |
| LTM Mar 2026 | $9.48M | +7.9% | +17.0% | 8.8% | |
| LTM Mar 2026 | $1.98M | -86.0% | -44.1% | 23.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $63K | — | — | 0.6% |
| Peer median (excluding XGN) | $15.41M | +10.1% | +7.0% | 32.0% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.